"Enhanced transmissibility, infectivity and immune resistance of the SARS-CoV-2 Omicron XBB.1.5 variant"
The Lancet Infectious Diseases Online January 31, 2023 doi:10.1016/S1473-3099(23)00051-8
New Study Shows SARS-CoV-2 Omicron XBB.1.5 Variant is Highly Transmissible and Infectious
Description
Published Article
Keiya Uriu1,2, Jumpei Ito1, Jiri Zahradnik3,4, Shigeru Fujita1,2, Yusuke Kosugi1,2, Gideon Schreiber3, The Genotype to Phenotype Japan (G2P-Japan) Consortium, Kei Sato1,2,5,6,7,8,9
1Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
2Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
3Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel
4First Medical Faculty at Biocev, Charles University, Vestec-Prague, Czechia
5International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
6International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
7Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan
1Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
2Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
3Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel
4First Medical Faculty at Biocev, Charles University, Vestec-Prague, Czechia
5International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
6International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
7Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan
